MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Substantia nigra"

  • 2023 International Congress

    The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF

    W. Powell, A. Newman-Tancredi, L. Annett, R. Depoortere, M. Iravani (Hatfield, United Kingdom)

    Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…
  • 2023 International Congress

    Diagnosis of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy with 7T-MRI substantia nigra imaging

    D. Su, Z. Zhang, Z. Zhang, T. Wu, J. Jing, T. Feng (Beijing, China)

    Objective: To detect the signal change of nigrosome-1 in 7T-MRI and its diagnostic and differential diagnostic efficacy as the imaging biomarker of PD, MSA-P, MSA-C…
  • 2023 International Congress

    Case report- Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 3 year follow up

    S. Sathyanarayana, J. Pasquini, D. Ledingham, D. Mitra, N. Warren, N. Pavese (Newcastle Upon Tyne, United Kingdom)

    Objective: To describe a case report of a rare cause of Parkinsonism Background: Vascular malformations such as cerebral cavernomas are known to predispose to haemorrhagic…
  • 2023 International Congress

    An in-vivo study of the integrity of the nigrostriatal pathways in drug-naive Parkinson’s disease patients using [11C]PE2I PET and neuromelanin-Magnetic Resonance Imaging

    G. Pagano, H. Wilson, E. de Natale, F. Niccolini, S. Polychronis, T. Yousaf, R. Gunn, E. Rabiner, M. Mehta, M. Politis (Basel, Switzerland)

    Objective: This study evaluated the relationship between the neurodegeneration of the substantia nigra neurons, assessed using Neuromelanin-sensitive MRI, and of the loss of striatal dopaminergic…
  • 2023 International Congress

    Agreement between swallow tail sign asymmetry and clinical laterality in Parkinson’s disease

    M. Rohonczi, G. Perlaki, G. Hernádi, N. Kovács (Pécs, Hungary)

    Objective: Our goal was to evaluate the concordance between asymmetry in nigral hyperintensity detected with 3T MRI and clinical symptomatology. Background: A promising MRI marker…
  • 2023 International Congress

    Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial

    J. Suescun, M. Schiess, E. Rodarte, C. Adams, T. Ellmore (Houston, USA)

    Objective: To select the most effective number of repeat doses of mesenchymal stem cells (MSC) delivered intravenously to slow the progression of Parkinson’s disease (PD).…
  • 2023 International Congress

    Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?

    M. Salvatore, E. Kasanga, Y. Han, R. Mcmanus, W. Navarrete, V. Nejtek, J. Richardson (Fort Worth, USA)

    Objective: To determine if GDNF receptor expression levels in the striatum or substantia nigra (SN) change in relation to differences in tyrosine hydroxylase (TH) and…
  • 2023 International Congress

    Sex differences for clinicopathological correlations in people with Lewy body pathology

    E. Bayram, D. Coughlin, I. Litvan (La Jolla, USA)

    Objective: To determine sex-specific clinical correlations of different Lewy body (LB), Alzheimer’s disease (AD) pathology staging and nigral neuron loss levels in people with LB…
  • 2023 International Congress

    Understanding Social Isolation before, during and after the Covid-19 pandemic among Patients with Parkinson’s disease

    A. Mehta, S. Ng, N. Chia, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan (Singapore, Singapore)

    Objective: The aim of this study was to understand and measure the effect of social network support in patients with Parkinson’s disease(PwP) before, during and…
  • 2022 International Congress

    Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment

    A. Naskar, S. M, S. Sengupta, P. Pal, P. Alladi (Bengaluru, India)

    Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley